Skip to main content

The independent medical news service

Breast cancer

01-04-2020 | Oncology | News | Article

Breast cancer treatments may ward off Alzheimer’s disease

Research suggests that women who use hormone-modulating breast cancer treatments such as tamoxifen or aromatase inhibitors may experience a reduced risk for neurodegenerative disease.

12-03-2020 | Oncology | News | Article

Metastases progression linked to deteriorating HRQoL

Disease progression among patients with metastatic lung, pancreatic, colorectal, and breast cancer is associated with statistically significant and clinically relevant reductions in health-related quality of life, real-world study data show.

17-12-2019 | Oncology | News | Article

TAPPS shows no difference in outcomes by talc delivery method

Individuals with malignant pleural effusion undergoing talc pleurodesis have comparable outcomes regardless of how the talc is delivered, shows a phase 3 trial reported in JAMA.

12-12-2019 | Oncology | News | Article

Ambulation outcomes not quite noninferior with single vs multifraction radiotherapy

Researchers have been unable to show that single-dose radiotherapy is not inferior to multifraction radiotherapy in terms of ambulatory status in patients with metastatic prostate, lung, or breast cancer and spinal cord or cauda equina compression.

02-05-2019 | Oncology | News | Article

Biologic, genetic markers predict radiation toxicity in oncology patients

A combination of biologic and genetic markers may be useful to predict which patients will experience toxicity following radiotherapy, suggest data presented at the ESTRO 38 conference in Milan, Italy.

23-04-2019 | Oncology | News | Article

SABR may improve survival in oligometastatic cancer

The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.

01-04-2019 | Oncology | News | Article

Mesothelin-targeted CAR T-cell therapy shows promise for malignant pleural disease

Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

07-02-2019 | Breast cancer | News | Article

Celecoxib may be contraindicated for some breast cancer patients

Use of the cyclooxygenase 2 inhibitor celecoxib during neoadjuvant taxane-based chemotherapy is associated with adverse survival outcomes in certain subgroups of patients with breast cancer, shows a post-hoc analysis of the REMAGUS02 trial.

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

24-01-2019 | Breast cancer | News | Article

TILs linked to HER2-positive breast cancer treatment outcomes

Tumour-infiltrating lymphocytes could serve as a prognostic marker in patients with early-stage HER2-positive breast cancer being treated with chemotherapy plus trastuzumab, indicates an analysis of the ShortHER trial comparing 9 weeks of trastuzumab with the standard 1-year regimen.

13-12-2018 | Breast cancer | News | Article

Trastuzumab emtansine targets residual invasive HER2-positive breast cancer

Adjuvant trastuzumab emtansine halves the risk of invasive disease recurrence or death versus trastuzumab in patients with residual invasive human epidermal growth factor receptor 2-positive early breast cancer, researchers report.

03-12-2018 | Oncology | News | Article

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

08-11-2018 | Oncology | Main feed | News

TRAIN-2 questions neoadjuvant anthracycline use for HER2-positive breast cancer

Carboplatin plus taxane neoadjuvant chemotherapy may be sufficient for women undergoing dual HER2 blockade for stage II–III HER2-positive breast cancer, findings from the TRAIN-2 study suggest.

06-11-2018 | Oncology | Main feed | News

Early risers may have reduced breast cancer risk

Women who function better earlier in the day, so-called morning people, are less likely to develop breast cancer than those who consider themselves night owls, suggests a Mendelian randomization analysis.

06-11-2018 | Oncology | Main feed | News

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.

05-11-2018 | Breast cancer | Main feed | News

Epigenetic therapy shows promise for HR-positive advanced breast cancer

Supplementing exemestane with the selective histone deacetylase inhibitor chidamide significantly prolongs the progression-free survival of women with hormone receptor-positive, HER2-negative advanced breast cancer, phase III trial findings indicate.

25-10-2018 | Oncology | News | Article

Atezolizumab combination improves advanced TNBC survival

First-line treatment with the programmed cell death ligand 1 inhibitor atezolizumab plus nab-paclitaxel has achieved a significant progression-free survival advantage over taxane chemotherapy alone in patients with metastatic triple-negative breast cancer, research suggests.

23-10-2018 | Oncology | News | Article

Serum testing reveals tamoxifen therapy nonadherence

Serum analysis suggests that within a year of beginning endocrine therapy after early breast cancer treatment, around one in six premenopausal women are no longer adherent to tamoxifen.

12-10-2018 | Breast cancer | News | Article

Endocrine therapy impacts cardiovascular risk in women with breast cancer

Long-term use of adjuvant endocrine therapy by women with a history of nonmetastatic breast cancer can significantly alter their risk for some types of cardiovascular disease, a meta-analysis shows.

11-10-2018 | Breast cancer | News | Article

Postmenopausal weight loss linked to reduced breast cancer risk

Postmenopausal women who lose weight have a lower risk for breast cancer than those who maintain a stable weight, report researchers.

Image Credits